Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07224555
Enrolling by invitation Not applicable

Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair

NCT07224555 · tracked via the Priya Life Science USA tracker
Sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Phase
Not applicable
Started
2025-03-27
Last updated
2026-06-08

Condition(s) studied

Hair Thinning

Investigational drug(s) / intervention(s)

Xtressé Hair Growth Gummies

Xtressé Hair Growth Gummies: The nutraceutical supplement is powered by proprietary X-3 BioActive Blend and contains plant based extracts and regenerative compounds not commonly found in existing hair supplements.

Study summary

The goal of this study is to determine how safe and effective it is to improve hair growth using an active gummy treatment in women with self-perceived thinning hair.

The main aims of this trial are:

1. To confirm using photographic analysis, changes in the quality, volume, and thickness of hair.
2. To gauge patient satisfaction with hair changes and application process.
3. Monitor and report any adverse events associated with the daily intake of Xtressé

Participants who qualify will complete 5 visits after voluntary consent has been given. Participants will be given a 30-day supply of the gummies at each visit over a 4-month period. Photographs and scalp analysis will be performed at each visit to measure changes in hair volume, thickness, and growth.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Women aged 18-65 years with self-perceived thinning hair (confirmed by an investigator). * Fitzpatrick skin types I to VI. * Ability and willingness to comply with the study protocol. * Commitment to using effective contraception throughout the study if of childbearing potential. Exclusion Criteria: * Pregnancy, nursing, or recent initiation of hormone therapy. * Change in other hair treatments within 3 months prior to the study. * Known uncontrolled health conditions (e.g., poorly controlled diabetes, hypertension). * History of hair or scalp disorders that could interfere with study results. * History of metabolic syndrome.

Primary outcome measure(s)

  • Hair Density Changes measured by SOCAi — From enrollment to the end of the study at 4 months
    Images will be captured using the the SOCAi system at baseline and Days 30, 60, 90, and 120, to evaluate hair density changes.
  • Within-subject increase in hair density assessed via Canfield HairMetrix® Phototrichogram Analysis — From enrollment to the end of treatment at 4 months
    Quantitative hair measurements calculated by analyzing the participants digital images from baseline to 4 months after taking Xtressé™ Supplements. Measurements of density as measured hair per cm².
  • Within-subject increase in hair thickness assessed via Canfield HairMetrix® Phototrichogram Analysis — From enrollment to the end of treatment at 4 months
    Quantitative hair measurements calculated by analyzing the participants digital images from baseline to 4 months after taking Xtressé™ Supplements. Measurements of follicular unit vellus/terminal ratio.

Trial sites (4)

FacilityCityRegionStatus
Advanced Dermatology & Cosmetic Surgery Maitland Florida
Hair Medicine Institute Alpharetta Georgia
Kindred Hair and Skin Marriottsville Maryland
Root Hair Institute Bellevue Washington

More Restore Biologics Holdings, Inc. dba Xtressé trials in the USA

Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia Enrolling by invitation
Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair Enrolling by invitation
Study to Evaluate Xtresse Serum in Individuals With Thinning Hair Active, not recruiting
XVIE to Treat Androgenetic Alopecia (AGA) Starting soon

Other trials for the same condition

Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia Enrolling by invitation
Clinical Study to Evaluate the Impact of Nutraceutical Supplements in Participants With Self-Perceived Thinning Hair Starting soon
Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning Active, not recruiting
Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07224555 on ClinicalTrials.gov ↗ ← All trials in the USA